Jennifer N Brudno1, Robert P T Somerville1, Victoria Shi1, Jeremy J Rose1, David C Halverson1, Daniel H Fowler1, Juan C Gea-Banacloche1, Steven Z Pavletic1, Dennis D Hickstein1, Tangying L Lu1, Steven A Feldman1, Alexander T Iwamoto1, Roger Kurlander1, Irina Maric1, Andre Goy1, Brenna G Hansen1, Jennifer S Wilder1, Bazetta Blacklock-Schuver1, Frances T Hakim1, Steven A Rosenberg1, Ronald E Gress1, James N Kochenderfer2. 1. Jennifer N. Brudno, Robert P.T. Somerville, Victoria Shi, Jeremy J. Rose, David C. Halverson, Daniel H. Fowler, Juan C. Gea-Banacloche, Steven Z. Pavletic, Dennis D. Hickstein, Tangying L. Lu, Steven A. Feldman, Alexander T. Iwamoto, Brenna G. Hansen, Bazetta Blacklock-Schuver, Frances T. Hakim, Steven A. Rosenberg, Ronald E. Gress, and James N. Kochenderfer, National Cancer Institute; Roger Kurlander and Irina Maric, National Institutes of Health, Bethesda; Jennifer S. Wilder, Frederick National Laboratory for Cancer Research, Frederick, MD; and Andre Goy, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ. 2. Jennifer N. Brudno, Robert P.T. Somerville, Victoria Shi, Jeremy J. Rose, David C. Halverson, Daniel H. Fowler, Juan C. Gea-Banacloche, Steven Z. Pavletic, Dennis D. Hickstein, Tangying L. Lu, Steven A. Feldman, Alexander T. Iwamoto, Brenna G. Hansen, Bazetta Blacklock-Schuver, Frances T. Hakim, Steven A. Rosenberg, Ronald E. Gress, and James N. Kochenderfer, National Cancer Institute; Roger Kurlander and Irina Maric, National Institutes of Health, Bethesda; Jennifer S. Wilder, Frederick National Laboratory for Cancer Research, Frederick, MD; and Andre Goy, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ. kochendj@mail.nih.gov.
Abstract
PURPOSE: Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the transplant donor. DLIs frequently are not effective at eradicating malignancy and often cause graft-versus-host disease, a potentially lethal immune response against normal recipient tissues. METHODS: We conducted a clinical trial of allogeneic T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19. Patients with B-cell malignancies that had progressed after alloHSCT received a single infusion of CAR T cells. No chemotherapy or other therapies were administered. The T cells were obtained from each recipient's alloHSCT donor. RESULTS: Eight of 20 treated patients obtained remission, which included six complete remissions (CRs) and two partial remissions. The response rate was highest for acute lymphoblastic leukemia, with four of five patients obtaining minimal residual disease-negative CR. Responses also occurred in chronic lymphocytic leukemia and lymphoma. The longest ongoing CR was more than 30 months in a patient with chronic lymphocytic leukemia. New-onset acute graft-versus-host disease after CAR T-cell infusion developed in none of the patients. Toxicities included fever, tachycardia, and hypotension. Peak blood CAR T-cell levels were higher in patients who obtained remissions than in those who did not. Programmed cell death protein-1 expression was significantly elevated on CAR T cells after infusion. Presence of blood B cells before CAR T-cell infusion was associated with higher postinfusion CAR T-cell levels. CONCLUSION: Allogeneic anti-CD19 CAR T cells can effectively treat B-cell malignancies that progress after alloHSCT. The findings point toward a future when antigen-specific T-cell therapies will play a central role in alloHSCT.
PURPOSE: Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the transplant donor. DLIs frequently are not effective at eradicating malignancy and often cause graft-versus-host disease, a potentially lethal immune response against normal recipient tissues. METHODS: We conducted a clinical trial of allogeneic T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19. Patients with B-cell malignancies that had progressed after alloHSCT received a single infusion of CAR T cells. No chemotherapy or other therapies were administered. The T cells were obtained from each recipient's alloHSCT donor. RESULTS: Eight of 20 treated patients obtained remission, which included six complete remissions (CRs) and two partial remissions. The response rate was highest for acute lymphoblastic leukemia, with four of five patients obtaining minimal residual disease-negative CR. Responses also occurred in chronic lymphocytic leukemia and lymphoma. The longest ongoing CR was more than 30 months in a patient with chronic lymphocytic leukemia. New-onset acute graft-versus-host disease after CAR T-cell infusion developed in none of the patients. Toxicities included fever, tachycardia, and hypotension. Peak blood CAR T-cell levels were higher in patients who obtained remissions than in those who did not. Programmed cell death protein-1 expression was significantly elevated on CAR T cells after infusion. Presence of blood B cells before CAR T-cell infusion was associated with higher postinfusion CAR T-cell levels. CONCLUSION: Allogeneic anti-CD19 CAR T cells can effectively treat B-cell malignancies that progress after alloHSCT. The findings point toward a future when antigen-specific T-cell therapies will play a central role in alloHSCT.
Authors: James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg Journal: J Immunother Date: 2009-09 Impact factor: 4.456
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2005-12 Impact factor: 5.742
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-01-23 Impact factor: 22.113
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari Journal: Blood Date: 1995-09-01 Impact factor: 22.113
Authors: Kirsty J Thomson; Emma C Morris; Adrian Bloor; Gordon Cook; Don Milligan; Anne Parker; Fiona Clark; Lynny Yung; David C Linch; Ronjon Chakraverty; Karl S Peggs; Stephen Mackinnon Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo Journal: J Exp Med Date: 2005-10-03 Impact factor: 14.307
Authors: Isabelle Magalhaes; Ingrid Kalland; James N Kochenderfer; Anders Österborg; Michael Uhlin; Jonas Mattsson Journal: J Immunother Date: 2018 Feb/Mar Impact factor: 4.456
Authors: Susanne H Baumeister; Joana Murad; Lillian Werner; Heather Daley; Helene Trebeden-Negre; Joanina K Gicobi; Adam Schmucker; Jake Reder; Charles L Sentman; David E Gilham; Frédéric F Lehmann; Ilene Galinsky; Heidi DiPietro; Kristen Cummings; Nikhil C Munshi; Richard M Stone; Donna S Neuberg; Robert Soiffer; Glenn Dranoff; Jerome Ritz; Sarah Nikiforow Journal: Cancer Immunol Res Date: 2018-11-05 Impact factor: 11.151
Authors: Christopher A Klebanoff; Joseph G Crompton; Anthony J Leonardi; Tori N Yamamoto; Smita S Chandran; Robert L Eil; Madhusudhanan Sukumar; Suman K Vodnala; Jinhui Hu; Yun Ji; David Clever; Mary A Black; Devikala Gurusamy; Michael J Kruhlak; Ping Jin; David F Stroncek; Luca Gattinoni; Steven A Feldman; Nicholas P Restifo Journal: JCI Insight Date: 2017-12-07